Sigma Life Science has released a range of engineered mammalian cell lines exploiting CompoZr zinc finger nuclease (ZFN) technology, for drug discovery and fundamental research applications.
By exploiting the genomic editing capabilities of ZFNs, Sigma's scientists can rapidly manufacture stable cell lines with precise, well-characterised genetic manipulations.
'CompoZr ZFN technology enables scientists to generate precisely controlled additions, deletions and modifications to the genome of a living cell,' said Dr Supriya Shivakumar, global commercial marketing manager for functional genomics at Sigma Life Science.
The programme will use ZFNs to incorporate and develop cell lines with a variety of cellular markers expected to aid in compound screening studies and biochemical pathway analysis, as well as specific isogenic lines designed to advance colorectal and breast cancer research.
In addition, Sigma offers a custom cell line engineering service, creating bespoke cell lines to match researchers' applications.
